SCHEMBL3760100

SCHEMBL3760100

O=Cc1ccn[c]c1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
MEN1 O00255 3/20 0.38
LMNA P02545 2/20 0.38
THRB P10828 1/20 0.38
BLM P54132 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
PTGS2 P35354 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TRIM24 O15164 2/20 0.32
TRIM33 Q9UPN9 2/20 0.32
TSHR P16473 1/20 0.32
CYP2A6 P11509 2/20 0.32
ERN1 O75460 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27829285 0.76 TRIM24 (0.36) KMT2AMEN1LMNATHRBBLM
SCHEMBL435001 0.72 LRRK2 (0.39) NPC1RAB9AALDH1A1CYP2A6NOTUM
SCHEMBL2399248 0.71 NOTUM (0.34) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL3759980 0.71 PDE10A (0.36) KMT2AMEN1TDP1NPC1RAB9A
SCHEMBL3751748 0.71 BACE1 (0.38) KMT2AMEN1LMNABLMTDP1
SCHEMBL3759693 0.71 CYP2A6 (0.37) KMT2AMEN1LMNANPC1RAB9A
SCHEMBL3758939 0.71 ALDH1A1 (0.37) KMT2AMEN1LMNATHRBTDP1
SCHEMBL3759347 0.70 ALDH1A1 (0.41) LMNABLMTDP1NPC1RAB9A
SCHEMBL3758958 0.70 SMN1; SMN2 (0.33) KMT2AMEN1PTGS2RAB9AALDH1A1
SCHEMBL3765736 0.68 PTGS2 (0.37) KMT2ALMNATHRBPTGS2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KMT2A 2175/4885MEN1 2762/4885LMNA 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.